Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.

NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41

Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol (2010) 5.61

Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06

The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem (2007) 5.06

Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24

Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54

Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23

Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53

Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet (1997) 2.39

Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer (1991) 1.77

A new world of Polycombs: unexpected partnerships and emerging functions. Nat Rev Genet (2013) 1.67

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol (2010) 1.59

CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell (2013) 1.53

Targeting EZH2 in cancer. Nat Med (2016) 1.51

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res (2010) 1.41

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.34

Neurofibromin: a general outlook. Clin Genet (2006) 1.31

Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27

Malignant peripheral nerve sheath tumors. Oncologist (2014) 1.23

Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol (2013) 1.22

Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.19

Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol (2003) 1.06

BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep (2013) 1.01

EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol (2014) 0.93

Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer (2015) 0.89

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol (2015) 0.86

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat (2012) 0.86

TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors. J Neurooncol (2014) 0.83

TP53 mutation analysis of malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol (2010) 0.81

Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res (2013) 0.81

Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection. Mol Oncol (2015) 0.77

High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia. Br J Cancer (2012) 0.77

Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol (2014) 0.93

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. Mol Oncol (2017) 0.83

ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. Cancer Treat Rev (2016) 0.78

Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice. Br J Pharmacol (2016) 0.77

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. Eur J Cancer (2017) 0.75